Sihuan Pharmaceutical Holdings Group (HKG:0460) made a capital increase in Hainan Meifu Medical Device to increase its presence in the aesthetics market, according to a Tuesday filing with the Hong Kong bourse.
Meiyan Space, a non-wholly owned subsidiary of Sihuan, will invest 25.5 million yuan, while Hainan Temmei, a connected party but not a subsidiary of the company, will invest 23.5 million yuan.
This move raised Meifu's registered capital to 50 million yuan, with Meiyan holding 51% and Hainan Temmei 49%.
The pharmaceutical company's shares were 5% higher in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。